Real-life results of the treatment with lutetium in advanced neuroendocrine tumours

#4345

Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.

Aim(s): To evaluate the overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and toxicity of the patients with unresectable NETs who were treated with 177LU in the medical centres of our region, from 2017 to 2024.

Materials and methods: Retrospective study of all the patients with unresectable NETs who were treated with 177LU in the two medical centres of our region from 2017 to 2024. Descriptive and survival analyses were performed using Jamovi.

Conference:

Presenting Author: Campos Ramírez S

Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,

Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,